$TGTX News

TG Therapeutics (NASDAQ:TGTX) Meets Minervini's Trend Template with Accelerating Growth

TG Therapeutics to Host Conference Call on Second Quarter 2026 Financial Results and Business Update

TG Therapeutics (TGTX) to Report Q2 Results: Wall Street Expects Earnings Growth

B. Riley Securities Maintains Buy on TG Therapeutics, Raises Price Target to $86

How Roche Unexpectedly Buoyed IBD Stock Of The Day TG Therapeutics

TG Therapeutics (TGTX) Gains as Its Key Drug Exceeded Expectations

HC Wainwright & Co. Maintains Buy on TG Therapeutics, Raises Price Target to $77

TG Therapeutics (TGTX) Starts Phase 2 Briumvi Trial

TG Therapeutics (TGTX) Stock May Still Be Cheap Despite New Trial News

Can TG Therapeutics' (TGTX) Schizophrenia Trial Meaningfully Redefine BRIUMVI’s Role Beyond Multiple Sclerosis?

Is TG Therapeutics (TGTX) Fully Valued Following Its Schizophrenia Trial Update?

TGTX Stock Rises On Wall Street Price Target Hike, New Schizophrenia Trial Launch

B of A Securities Maintains Underperform on TG Therapeutics, Raises Price Target to $20

HC Wainwright & Co. Reiterates Buy on TG Therapeutics, Maintains $70 Price Target

TG Therapeutics Announces Initiation of Phase 2 Trial Evaluating BRIUMVI in Patients with Treatment-Resistant Schizophrenia

TG Therapeutics Starts Phase 2 Clinical Study Of BRIUMVI In Adult Participants With Treatment-Resistant Schizophrenia

Will Briumvi's Strength Continue to Aid TGTX's Top Line in Q2?

TG THERAPEUTICS INC (NASDAQ:TGTX): High-Growth Momentum Meets Minervini Trend Template Technical Strength

Is TG Therapeutics, Inc. (TGTX) A Good Stock To Buy Now?

TG Therapeutics Stock Is On A Hot Streak: Why It's Up 79% And Climbing